In this episode we take a look at the recent section 56 exemption approved by Health Canada for psilocybin use in four terminally ill cancer patients. This approval represents a huge step forward in the treatment of mental health disorders and could have some interesting implications. Link to my October 2019 paper: https://www.docdroid.net/CmPlLos/marijuana-as-an-entryway-to-psychedelic-therapy-docx

In this episode we examine what the current landscape of mental health therapies looks like along with the pressures of the current global health climate in terms of driving innovation. If you would like to read the studies cited in the cast they can be found here: Fava and Davidson, 1996: https://pubmed.ncbi.nlm.nih.gov/8827185/ Rush, 2006: https://pubmed.ncbi.nlm.nih.gov/17074942/ Samples, 2016: https://ps.psychiatryonline.org/doi/pdfplus/10.1176/appi.ps.201400021 Pratt, 2017: https://www.cdc.gov/nchs/products/databriefs/db283.htm Wu, 2005: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320475/ Liu, 2006: https://www.sciencedirect.com/science/article/pii/S0010440X11000216 Wu, 2006: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720767/ I also highly recommend reading this paper for a brief overview of the history of mental health therapies beyond what I had time to mention in the cast: Hillhouse, 2015: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428540/

In this episode we examine the initial development of 18-MC from ibogaine and review three of the pioneering studies performed by Dr. Stanley Glick that allowed future research into 18-MC to be possible. If you would like to read the 1991 study it can be found here: https://www.ncbi.nlm.nih.gov/pubmed/1868880 If you would like to read the 1996 study it can be found here: https://www.ncbi.nlm.nih.gov/pubmed/8782860 If you would like to read the 2000 study it can be found here: https://www.ncbi.nlm.nih.gov/pubmed/11085336  I have also done a short write up summarizing the 2000 paper which can be found here: https://www.docdroid.net/MoP6P2V/18-mc-analysis-of-efficacy-and-safety-pdf

An analysis of Mind Medicine's recently initiated clinical trial investigating the safety of 18-methoxycoronaridine (18-MC) for use in a human population.  The study design can be found here: https://clinicaltrials.gov/ct2/show/NCT04292197